This year’s ASCO was undoubtedly an outstanding meeting, featuring a series of highly relevant studies, many of which were simultaneously published in the New England Journal of Medicine.
A range of new compounds and strategies for difficult-to-treat entities, including small cell lung cancer, glioblastomas and others, as well as several new adjuvant strategies in head and neck and non-melanoma skin cancers, were presented.
Let me zoom in on a number of news items in gastrointestinal cancers:
A lesson recalled by DYNAMIC: a good prognostic factor doesn’t make a predictive one. The high hopes that post-operative ctDNA in local or locally advanced colorectal cancer would successfully guide the adjuvant management proved wrong. While ctDNA is clearly a powerful prognostic factor, whatever type of intense adjuvant treatment chosen for the ctDNA-defined worse prognostic group did not change outcomes for the affected patients.
Otherwise, there’s good news for patient with metastatic BRAF-mutated tumours, where immunotherapy has proven beneficial when combined with neo-adjuvant chemotherapy in oesophageal cancer – and there finally seems to be something moving again in pancreatic cancer – with an attractive new neo adjuvant treatment in borderline- or non resectable disease, and new compounds /devices to treat advanced disease.
Of course, there were many more exciting developments to report, and we present only a selection thereof in this publication. I apologise in advance if a pertinent report you were looking for is not included.
Enjoy reading this year’s Medicom ASCO report
Yours sincerely,
Stefan Rauh
Biography
Dr Stefan Rauh is currently working as an oncologist/ haematologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is primarily involved in clinical work but also in research and teaching activities, and is interested in public policy and international cooperation projects in oncology. He has been a member of the ESMO Practising Oncologists’ Working Group since 2011 (chair 2014–2018), a member of the ESMO Public Policy Committee, and was an ESMO Executive Board member from 2015 to 2016. He is a co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.Conflict of Interest Statement: Nothing to declare.
Posted on
Table of Contents: ASCO 2025
Featured articles
ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer
Meet the expert: Prof. Marc Thill on the results of Datopotamab deruxtecan in the TROPION-Breast01 study
Head and Neck Cancer
Nivolumab addition to cisplatin-radiotherapy sets the first new post-operative standard for head-and-neck cancer in two decades
De-escalation: same survival, less vomiting
Antibody-drug conjugate outperforms chemotherapy
Skin Cancer
No added benefit of relatlimab in the adjuvant melanoma setting
Adjuvant BRAF/MEK-inhibition is safe and feasible in stage IIB/C BRAF V600-mutant melanoma
Adjuvant cemiplimab slashes recurrence risk in high-risk CSCC
Gynaecological Cancer
Timing of cytoreductive surgery does not impact overall survival in ovarian cancer
Dostarlimab (modestly) improves progression-free survival in advanced ovarian cancer
Glucocorticoid receptor antagonist bypasses platinum resistance in ovarian cancer
Non-inferior disease-free survival after sentinel lymph node biopsy in cervical cancer
Other
Anlotinib prolongs progression-free survival in glioblastoma
Colorectal Cancer
Anlotinib non-inferior to bevacizumab in first-line treatment of mCRC
BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment
ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer
Postoperative ctDNA positivity signals poor prognosis in stage 3 colon cancer, despite chemotherapy escalation
Breast Cancer
Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC
Vepdegestrant outperforms fulvestrant in ESR1-mutant advanced breast cancer
neoCARHP trial supports carboplatin omission in select HER2-positive early breast cancers
T-DXd plus pertuzumab sets first-line standard in HER2-positive metastatic breast cancer
ctDNA-guided switch to camizestrant delays progression in ESR1-mutated breast cancer
Ipatasertib-fulvestrant combination extends PFS after CDK4/6 inhibitor failure in ER+/HER2- metastatic breast cancer
Meet the expert: Prof. Marc Thill on the results of Datopotamab deruxtecan in the TROPION-Breast01 study
Gastric/Pancreatic Cancer
Elraglusib improves survival in untreated metastatic pancreatic cancer
TTFields therapy promotes survival benefit in unresectable pancreatic cancer
Neoadjuvant PAXG regimen doubles 3-year EFS over mFOLFIRINOX in resectable pancreatic cancer
DESTINY delivered: Trastuzumab deruxtecan extends survival in HER2-positive gastric cancer
MATTERHORN: Durvalumab plus FLOT significantly improves event-free survival in resectable gastric/GEJ adenocarcinoma
Satricabtagene autoleucel improves survival in advanced gastric and GEJ cancers
Genitourinary Cancer
AMPLITUDE boosts radiographic PFS with niraparib in HRR-mutated mCSPC
Double the impact with less BCG: Mitomycin combo maintains efficacy in NMIBC
Haematological Cancer
Rusfertide improved symptoms and quality-of-life in polycythaemia vera
Zilovertamab vedotin: early efficacy in relapsed or refractory DLBCL in combination with R-GemOx?
Glofitamab combination sustains long-term benefit in relapsed/refractory DLBCL
Long-term zanubrutinib efficacy in high-risk CLL/SLL patients with del(17p)
Lung Cancer
Patritumab deruxtecan shows PFS, but no OS-benefit in EGFR-mutant NSCLC
Neoadjuvant nivolumab improves overall survival in resectable NSCLC
Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC
A chemotherapy-free second-line option for MET-amplified EGFR-mutant NSCLC
Consolidation therapy with benmelstobart in stage III NSCLC
Tarlatamab is better than chemotherapy in second-line SCLC
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com